Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study

BACKGROUND: Treatment with antitumor necrosis factor alpha (anti-TNF-α) is safe and effective as first-line therapy; however, its efficacy is limited due to primary nonresponse (PNR) and secondary loss of response (LOR), resulting in treatment discontinuation in approximately 40%–50% of cases. Vedol...

Descripción completa

Detalles Bibliográficos
Autores principales: Bacsur, Péter, Matuz, Mária, Resál, Tamás, Miheller, Pál, Szamosi, Tamás, Schäfer, Eszter, Sarlós, Patrícia, Iliás, Ákos, Szántó, Kata, Rutka, Mariann, Bálint, Anita, Milassin, Ágnes, Fábián, Anna, Bor, Renáta, Szepes, Zoltán, Molnár, Tamás, Farkas, Klaudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806440/
https://www.ncbi.nlm.nih.gov/pubmed/36600684
http://dx.doi.org/10.1177/17562848221144349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806440/
https://www.ncbi.nlm.nih.gov/pubmed/36600684
http://dx.doi.org/10.1177/17562848221144349

Ejemplares similares